On September 17, 2024, Steven Collis, Chairman, President & Chief Executive Officer of Cencora Inc (COR, Financial), sold 21,509 shares of the company. The transaction was filed on the same day with the SEC. Following this sale, the insider now owns 285,088 shares of Cencora Inc.
Cencora Inc, formerly known as AmerisourceBergen, is a global healthcare company focused on improving the access and affordability of pharmaceuticals and healthcare products. The company operates through various segments, including Pharmaceutical Distribution and Strategic Global Sourcing.
Over the past year, the insider has sold a total of 203,921 shares and has not made any purchases. This recent transaction is part of a broader trend observed within the company, where there have been 30 insider sells and only 1 insider buy over the past year.
Shares of Cencora Inc were trading at $241.01 on the day of the transaction, giving the company a market cap of approximately $44.78 billion. The price-earnings ratio of the stock stands at 24.81, which is above both the industry median of 18.59 and the company's historical median.
The stock's valuation according to the GF Value is $211.39, resulting in a price-to-GF-Value ratio of 1.14, indicating that the stock is Fairly Valued. The GF Value is calculated based on historical trading multiples, an adjustment factor from GuruFocus, and future business performance estimates from analysts.
This insider sale might draw the attention of current and potential investors, especially considering the insider's significant reduction in holdings and the overall insider selling trend at Cencora Inc.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
